Century Therapeutics Reports Q2 Cash Runway Into 2029, FDA Alignment on CNTY-813 IND Path
IPSC has more than doubled off its 52-week low of $0.435.
Summary
Century Therapeutics reported Q2 2026 financials with $197.2M in cash, extending runway into early 2029 — a critical buffer for a pre-revenue biotech. R&D spending dropped to $19.6M from $26.9M a year ago, reflecting continued cost discipline. The real news is regulatory: a pre-IND meeting with the FDA yielded alignment on the nonclinical package, manufacturing, and Phase 1/2 trial design for lead T1D candidate CNTY-813, keeping the IND submission on track for Q4 2026. The company also established its Phase 1 manufacturing process with consistent quality across batches, de-risking the clinical timeline. CNTY-308, a CD19 CAR-iT for B-cell diseases, remains on track to enter the clinic this year. This follows the June ADA data presentation and the June 12 shareholder approval to increase authorized shares, which provided the equity flexibility now reflected in the cash position. Initial CNTY-813 clinical data is expected in 2H 2027.
At the time of this announcement, IPSC was trading at $2.07 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $371.5M. The 52-week trading range was $0.44 to $3.04. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.